All In Biotech

Drug Trial Radar · NCT03830827

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Efficacy of Mindfulness-based Relapse Prevention With or Without Vortioxetine on the Prevention of Relapse in Chronic Methamphetamine Users

Last checked: Nov 19, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

220

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Apr 30, 2021

Study completion Apr 30, 2021

Sponsor

Lead sponsor
Sir Run Run Shaw HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhen Mental Health Center; Huazhong University of Science and Technology
First posted
Feb 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, double-blind, Randomized, parallel-group study in subjects with methamphetamine dependence was to assess the efficacy of MBRP combined with vortioxetine and MBRP alone on 24-week abstinence rates, improvement of cognition and depressive symptoms.

Conditions

  • Relapse
  • Cognitive Impairment
  • Depression

Interventions

  • VortioxetineDrug

    8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Timeline Followback (TLFB) for MA relapse ratesTime frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.